Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Regulus Therapeutics has received 5 bullish ratings in the last quarter, which is a positive signal. Furthermore, the company's average 12-month price target has increased by 6.67% over the past month, indicating that analysts have a positive outlook on the company's future performance.